As of 2025-12-24, the Relative Valuation of Ultragenyx Pharmaceutical Inc (RARE) is (147.54) USD. This relative valuation is based on P/E multiples. With the latest stock price at 34.13 USD, the upside of Ultragenyx Pharmaceutical Inc based on Relative Valuation is -532.3%.
The range of the Relative Valuation is (131.74) - (144.24) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 19.5x - 24.0x | 21.8x |
| Forward P/E multiples | 21.9x - 32.8x | 27.4x |
| Fair Price | (131.74) - (144.24) | (147.54) |
| Upside | -486.0% - -522.6% | -532.3% |
| Date | P/E |
| 2025-12-23 | -5.68 |
| 2025-12-22 | -5.78 |
| 2025-12-19 | -5.57 |
| 2025-12-18 | -5.46 |
| 2025-12-17 | -5.53 |
| 2025-12-16 | -5.71 |
| 2025-12-15 | -6.03 |
| 2025-12-12 | -6.03 |
| 2025-12-11 | -6.02 |
| 2025-12-10 | -5.99 |
| 2025-12-09 | -6.04 |
| 2025-12-08 | -6.07 |
| 2025-12-05 | -6.05 |
| 2025-12-04 | -6.08 |
| 2025-12-03 | -6.07 |
| 2025-12-02 | -5.57 |
| 2025-12-01 | -5.55 |
| 2025-11-28 | -5.78 |
| 2025-11-26 | -5.62 |
| 2025-11-25 | -5.58 |
| 2025-11-24 | -5.45 |
| 2025-11-21 | -5.59 |
| 2025-11-20 | -5.19 |
| 2025-11-19 | -5.30 |
| 2025-11-18 | -5.46 |
| 2025-11-17 | -5.41 |
| 2025-11-14 | -5.50 |
| 2025-11-13 | -5.47 |
| 2025-11-12 | -5.58 |
| 2025-11-11 | -5.53 |
| 2025-11-10 | -5.31 |
| 2025-11-07 | -5.10 |
| 2025-11-06 | -5.15 |
| 2025-11-05 | -5.30 |
| 2025-11-04 | -5.40 |
| 2025-11-03 | -5.57 |
| 2025-10-31 | -5.76 |
| 2025-10-30 | -5.85 |
| 2025-10-29 | -5.76 |
| 2025-10-28 | -5.79 |
| 2025-10-27 | -5.88 |
| 2025-10-24 | -5.58 |
| 2025-10-23 | -5.60 |
| 2025-10-22 | -5.51 |
| 2025-10-21 | -5.69 |
| 2025-10-20 | -5.72 |
| 2025-10-17 | -5.43 |
| 2025-10-16 | -5.65 |
| 2025-10-15 | -5.56 |
| 2025-10-14 | -5.27 |